Growth and Adult Height during Human Growth Hormone Treatment in Chinese Children with Multiple Pituitary Hormone Deficiency Caused by Pituitary Stalk Interruption Syndrome: A Single Centre Study
The aim of this study was to assess growth velocity (GV) during hGH treatment of children with MPHD caused by PSIS and to analyze the characteristics of patients that attain normal adult heights. Data from 74 (58 males/16 females) children with MPHD caused by PSIS with GH, TSH, gonadotropin and ACTH deficiencies were collected. Subjects were divided into groups containing 12 pre-pubescent females (Female-Group) and 36 pre-pubescent males (Male-Group 1). The remaining 24 males were further sub-divided into 2 groups (Male-Group2 and Male-Group3) according to the initiation of gonadotropin treatment. We observed no differences in △HtSDS and GV at different time points of hGH treatment between Female- and Male-Group 1 (P > 0.05). The GV in the first year was higher than the second year of hGH treatment (P = 0.011 for Female-Group, P ≤ 0.001 for Male-Group 1, P = 0.005 for Male-Group 2, and P = 0.046 for Male-Group 3). Additionally, 23 (19 males and 4 females) patients reached adult height after treatment. The total gain in height positively correlated with the GV during the first year (R = 0.626, P≤ 0.001). GVs during hGH treatment were similar amongst pre-pubescent males and females with MPHD caused by PSIS. The GV during the first year of hGH treatment is therefore an effective predictor of future height outcomes in patients with MPHD caused by PSIS.